Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 2, 2012, Pages 164-171

  Fogari, Roberto ^a   Maffioli, Pamela ^a   Mugellini, Amedeo ^a   Zoppi, Annalisa ^a   Lazzari, Pierangelo ^a   Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

amlodipine; hypertension; insulin sensitivity; losartan; steatosis

Indexed keywords

AMLODIPINE; GLUCOSE; INSULIN; LOSARTAN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT; TREATMENT OUTCOME;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY LIVER; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; LIPIDS; LOSARTAN; MALE; MIDDLE AGED; SIMVASTATIN;

EID: 84855883859     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834ba188     Document Type: Article

References (46)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434-438. (Pubitemid 10057164)
2. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126:137-145. (Pubitemid 27058588)
3. Angulo P. Non-alcoholic fatty liver disease. N Engl J Med 2002; 346:1221-1226.
4. McCullough AJ. Update on nonalcoholic fatty liver disease. J ClinGastroenterol 2002; 34:255-262. (Pubitemid 34177381)
5. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology 2003; 37:1202-1219. (Pubitemid 36538699)
6. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40:S5-S10. (Pubitemid 44309537)
7. Brunt EM. Nonalcoholic steatohepatitis: Definition and pathology. Semin Liver Dis 2001; 21:3-16. (Pubitemid 32240482)
8. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172:899-905. (Pubitemid 40543601)
9. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol 2002; 17:S186-S190. (Pubitemid 34539308)
10. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al.; for the LIDO Study Group. . Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128:1898-1906. (Pubitemid 40824701)
11. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: Is biopsy necessary? Eur J. Gastroenterol. Hepatol 2003; 15:539-543. (Pubitemid 36571048)
12. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology 2002; 123:745-750. (Pubitemid 34977081)
13. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis 2001; 21:71-80. (Pubitemid 32240487)
14. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR 2007; 189:W320-W323.
15. Fujita K, Yoneda M, Wada K, Mawatari H, Takahashi H, Kirikoshi H. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci 2007; 52:3455-3464. (Pubitemid 350077187)
16. Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G. Nonalcoholic fatty liver and insulin resistance: A cause-effect relationship? Dig Liver Dis 2004; 36:165-173. (Pubitemid 41130632)
17. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51:797-802. (Pubitemid 34760191)
18. Dodson PM, Lip GY, Eames SM, Gibson JM, Beevers DG. Hypertensive retinopathy: A review of existing classification systems and a suggestion for a simplified grading system. J Hum Hypertens 1996; 10:93-98. (Pubitemid 26101031)
19. Hayreh SS. Classification of hypertensive fundus changes and their order of appearance. Ophthalmologica 1989; 198:247-260. (Pubitemid 19143852)
20. Walsh JB. Hypertensive retinopathy: Description, classification and prognosis. Ophthalmology 1982; 8:1127-1131. (Pubitemid 12003229)
21. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16:716-730.
22. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8:260-266.
23. Yamauchi T, Kamon J,Waki H, Terauchi Y, Kubota N, Hara K, et al. The fatderived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med 2001; 7:941-946. (Pubitemid 32756432)
24. Misra A, Garg A. Leptin: Its receptor and obesity. J Invest Med 1996; 44:540-548.
25. Zhang M, Tracey K. The cytokine handbook. 3rd ed. San Diego: Academic Press; 1988.
26. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated highsensitivity C-reactive protein assay. Clin Chem 1999; 45:2136-2141.
27. De Fronzo RA, Tobin JA, Andres B. Glucose clamp technique, a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:214-223.
28. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317:350-357. (Pubitemid 17118813)
29. Luef GJ, Waldmann M, Sturm W, Naser A, Trinka E, Unterberger I, et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol 2004; 55:729-732. (Pubitemid 38544334)
30. Pontiroli AE, Pizzocri P, Giacomelli M, Marchi M, Vedani P, Cucchi E, et al. Ultrasound measurement of visceral and subcutaneous fat in morbidly obese patients before and after laparoscopic adjustable gastric banding: Comparison with computerized tomography and with anthropometric measurements. Obes Surg 2002; 12:648-651. (Pubitemid 35305743)
31. Winer BJ. Statistical principles in experimental design. 2nd ed., New York: McGraw-Hill; 1971.
32. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279:32345-32353. (Pubitemid 39014687)
33. Kabir M, Catalano KJ, Ananthnarayan S, Kim SP, Van Citters GW, Dea MK, et al. Molecular evidence supporting the portal theory: A causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol 2005; 288:E454-E461. (Pubitemid 40110656)
34. Hausman GJ, Richardson RL. Adipose tissue angiogenesis. J Anim Sci 2004; 82:925-934. (Pubitemid 38572359)
35. Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA 2002; 99:10730-10735.
36. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med 2004; 10:625-632. (Pubitemid 38796854)
37. Trayhurn P, Wood IS. Adipokines: Inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92:347-355. (Pubitemid 40277057)
38. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112:1821-1830. (Pubitemid 38063705)
39. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante JAW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796-1808. (Pubitemid 38063703)
40. Matsuzawa Y. Therapy insight: Adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006; 3:35-42. (Pubitemid 43078211)
41. David CW, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: Molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 2005; 288:H2031-H2041. (Pubitemid 40604084)
42. Tritos NA, Mantzoros CS. Leptin: Its role in obesity and beyond. Diabetologica 1997; 40:1371-1379. (Pubitemid 28004929)
43. Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, Fogari E, et al. Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res 2011; 34:145-151.
44. Fogari R, Zoppi A, Mugellini A, Lazzari P, Derosa G. Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. Horm Metab Res 2010; 42:892-896.
45. Eriksson JW, Jansson PA, Carlberg B, Hägg A, Kurland L, Svensson MK, et al. Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: The mechanisms for the diabetes preventing effect of candesartan (MEDICA) study. Hypertension 2008; 52:1030-1037.
46. Derosa G, Maffioli P. Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. Expert Rev Cardiovasc Ther 2010; 8:835-843.